Docetaxel combined with trastuzumab is an active regimen in HER-2 3+ overexpressing and fluorescent in situ hybridization-positive metastatic breast cancer: A multi-institutional phase II trial

Journal of Clinical Oncology

Volumn 22, Issue 6, 2004, Pages 1071-1077

  Tedesco, K L ^a   Thor, A D ^a   Johnson, David H ^a   Shyr, Y ^a   Blum, K A ^a   Goldstein, L J ^a   Gradishar, W J ^a   Nicholson, B P ^a   Merkel, D E ^a   Murrey, D ^a   Edgerton, S ^a   Sledge Jr , G W ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; TRASTUZUMAB; ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 3; MONOCLONAL ANTIBODY; TAXOID;

ARTICLE; BREAST CANCER; BREAST METASTASIS; CANCER GROWTH; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE OVEREXPRESSION; HEART DISEASE; HUMAN; IMMUNOHISTOCHEMISTRY; MULTICENTER STUDY; ONCOGENE NEU; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SIDE EFFECT; ADULT; AGED; BREAST TUMOR; DISEASE FREE SURVIVAL; DRUG ANTAGONISM; GENE EXPRESSION REGULATION; METABOLISM; MIDDLE AGED; PATHOLOGY; SURVIVAL; UNITED STATES; UPREGULATION;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; MIDDLE AGED; RECEPTOR, ERBB-2; RECEPTOR, ERBB-3; SURVIVAL ANALYSIS; TAXOIDS; UNITED STATES; UP-REGULATION;

EID: 1842614241     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2004.10.046     Document Type: Article

References (37)

1. Pietras RJ, Fendly BM, Chazin VR, et al: Antibody to HER-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells. Oncogene 9:1829-1838, 1994
2. Burstein HJ, Kuter I, Campos SM, et al: Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast cancer. J Clin Oncol 19:2722-2730, 2001
3. Pegram MD, Lopez A, Konecny G, et al: Trastuzumab and chemotherapeutics: Drug interactions and synergies. Semin Oncol 27:21-25, 2000
4. Gusterson BA, Gelber RD, Goldhirsch A, et al: Prognostic importance of c-erbB-2 expression in breast cancer: International (Ludwig) Breast Cancer Study Group. J Clin Oncol 10: 1049-1056, 1992
5. Ravdin PM, Chamness GC: The c-erbB-2 proto-oncogene as a prognostic and predictive marker in breast cancer: A paradigm for the development of other macromolecular markers-A review. Gene 159:19-27, 1995
6. van de Vijver MJ, Peterse JL, Mooi WJ, et al: Neu-protein overexpression in breast cancer: Association with comedo-type ductal carcinoma in situ and limited prognostic value in stage II breast cancer. N Engl J Med 319:1239-1245, 1988
7. Baselga J, Tripathy D, Mendelsohn J, et al: Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J Clin Oncol 14:737-744, 1996
8. Vogel CL, Cobleigh MA, Tripathy D, et al: Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 20:719-726, 2002
9. Cobleigh MA, Vogel CL, Tripathy D, et al: Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 17:2639-2648, 1999
10. Pegram MD, Lipton A, Hayes DF, et al: Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. J Clin Oncol 16:2659-2671, 1998
11. Seidman AD, Fornier MN, Esteva FJ, et al: Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification. J Clin Oncol 19:2587-2595, 2001
12. Hancock MC, Langton BC, Chan T, et al: A monoclonal antibody against the c-erbB-2 protein enhances the cytotoxicity of cis-diamminedichloroplatinum against human breast and ovarian tumor cell lines. Cancer Res 51:4575-4580, 1991
13. Arteaga CL, Winnier AR, Poirier MC, et al: P185c-erbB-2 signal enhances cisplatin-induced cytotoxicity in human breast carcinoma cells: Association between an oncogenic receptor tyrosine kinase and drug-induced DNA repair. Cancer Res 54:3758-3765, 1994
14. Yap HY, Salem P, Hortobagyi GN, et al: Phase II study of cis-dichlorodiammineplatinum(II) in advanced breast cancer. Cancer Treat Rep 62:405-408, 1978
15. Slamon DJ, Leyland-Jones B, Shak S, et al: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344: 783-792, 2001
16. Mass R, Press M, Andersen S, et al: Improved survival benefit from Herceptin (trastuzumab) in patients selected by fluorescence in situ hybridization (FISH). Proc Am Soc Clin Oncol 20:22a, 2001 (abstr 85)
17. Verweij J, Clavel M, Chevalier B: Paclitaxel (Taxol) and docetaxel (Taxotere): Not simply two of a kind. Ann Oncol 5:495-505, 1994
18. Valero V: Docetaxel as single-agent therapy in metastatic breast cancer: Clinical efficacy. Semin Oncol 24:S13-11-S13-18, 1997 (suppl 13)
19. Cortes JE, Pazdur R: Docetaxel. J Clin Oncol 13:2643-2655, 1995
20. Crown J: A review of the efficacy and safety of docetaxel as monotherapy in metastatic breast cancer. Semin Oncol 26:5-9, 1999
21. Burstein HJ, Manola J, Younger J, et al: Docetaxel administered on a weekly basis for metastatic breast cancer. J Clin Oncol 18:1212-1219, 2000
22. Hainsworth JD, Burris HA 3rd, Yardley DA, et al: Weekly docetaxel in the treatment of elderly patients with advanced breast cancer: A Minnie Pearl Cancer Research Network phase II trial. J Clin Oncol 19:3500-3505, 2001
23. Valero V: Future direction of neoadjuvant therapy for breast cancer. Semin Oncol 25:36-41, 1998
24. Valero V, Holmes FA, Walters RS, et al: Phase II trial of docetaxel: A new, highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer. J Clin Oncol 13:2886-2894, 1995
25. Ravdin PM, Burris HA 3rd, Cook G, et al: Phase II trial of docetaxel in advanced anthracycline-resistant or anthracenedione-resistant breast cancer. J Clin Oncol 13:2879-2885, 1995
26. Nabholtz JM, North S, Smylie M, et al: Docetaxel (Taxotere) in combination with anthracyclines in the treatment of breast cancer. Semin Oncol 27:11-18, 2000
27. Pegram M, Hsu S, Lewis G, et al: Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers. Oncogene 18:2241-2251, 1999
28. Pegram MD, Finn RS, Arzoo K, et al: The effect of HER-2/neu overexpression on chemotherapeutic drug sensitivity in human breast and ovarian cancer cells. Oncogene 15:537-547, 1997
29. Chan S, Friedrichs K, Noel D, et al: Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer: The 303 Study Group. J Clin Oncol 17:2341-2354, 1999
30. Thor AD, Edgerton SM, Liu S, et al: Gelsolin as a negative prognostic factor and effector of motility in erbB-2-positive epidermal growth factor receptor-positive breast cancers. Clin Cancer Res 7:2415-2424, 2001
31. Thor AD, Liu S, Edgerton S, et al: Activation (tyrosine phosphorylation) of ErbB-2 (HER-2/neu): A study of incidence and correlation with outcome in breast cancer. J Clin Oncol 18:3230-3239, 2000
32. Simon R: Optimal two-stage designs for phase II clinical trials. Control Clin Trials 10:1-10, 1989
33. Kuzur M, Albain K, Huntington M, et al: A phase II trial of docetaxel and Herceptin in metastatic breast cancer patients overexpressing HER-2. Proc Am Soc Clin Oncol 19:131a, 2000 (abstr 512)
34. Meden H, Beneke A, Hesse T, et al: Weekly intravenous recombinant humanized anti-P185HER2 monoclonal antibody (Herceptin) plus docetaxel in patients with metastatic breast cancer: A pilot study. Anticancer Res 21:1301-1305, 2001
35. Esteva FJ, Valero V, Booser D, et al: Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer. J Clin Oncol 20: 1800-1808, 2002
36. Hainsworth JD, Burris HA 3rd, Erland JB, et al: Phase I trial of docetaxel administered by weekly infusion in patients with advanced refractory cancer. J Clin Oncol 16:2164-2168, 1998
37. Nabholtz JM, Reese DM, Lindsay MA, et al: Combination chemotherapy for metastatic breast cancer. Expert Rev Anticancer Ther 2:169-180, 2002